文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

2021/2022年秋冬季德国全国性基于人群的感染和疫苗诱导的SARS-CoV-2抗体血清阳性率

Nationwide population-based infection- and vaccine-induced SARS-CoV-2 antibody seroprevalence in Germany in autumn/winter 2021/2022.
PubMed 文献 · Euro Surveill · 2025-01-01

研究基于SOEP动态队列的干血斑样本,估计2021年11月至2022年3月德国≥14岁人群SARS-CoV-2抗体血清阳性率。合并血清阳性率未校正为90.7%(95%CI:89.7%-91.6%),校正灵敏度和抗体衰减后为94.6%(95%CI:93.6%-95.7%);感染诱导血清阳性率为11.3%(95%CI:9.1%-13.5%),基础免疫率为90%(95%CI:88.9-90.9%),主要来自疫苗接种;漏报因子为1.55(95%CI:1.3-1.8)。

要点

  • 合并血清阳性率未校正90.7%,校正后94.6%。
  • 感染诱导血清阳性率11.3%,基础免疫率90%。
  • 漏报因子估计为1.55(95%CI:1.3-1.8)。

核心结论

  • 在SARS-CoV-2奥密克戎波开始时,大多数人已接种疫苗、感染或两者兼有。
  • 大规模疫苗接种而非高感染率填补了免疫缺口,尤其在已知重症COVID-19风险较高的≥65岁人群中。
  • 数据指向需要针对社会经济、人口和区域分层采取缓解策略,包括提高疫苗接率的措施。

研究设计与样本

  • 第二项RKI-SOEP(RKI-SOEP-2)研究,基于嵌入社会经济面板(SOEP)动态队列的全国性人群样本,采用干血斑标本进行血清学分析,并结合同一受试者的问卷自报数据估计血清阳性率。
  • 研究时间为2021年11月至2022年3月,研究对象为≥14岁个体。

主要发现

  • 合并血清阳性率未校正为90.7%(95%CI:89.7%-91.6%),校正灵敏度和抗体衰减后为94.6%(95%CI:93.6%-95.7%)。
  • 九分之一个体曾感染,感染诱导血清阳性率为11.3%(95%CI:9.1%-13.5%)。
  • 十分之九个体具有基础免疫,基础免疫率为90%(95%CI:88.9-90.9%),主要来自疫苗接种。
  • 人群加权估计随年龄、地区和社会经济剥夺程度而异。
  • 漏报因子估计为1.55(95%CI:1.3-1.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundThe first Corona Monitoring Nationwide (RKI-SOEP) study (October 2020-February 2021) found a low pre-vaccine SARS-CoV-2 antibody seroprevalence (2.1%) in the German adult population (≥ 18 years).AimThe objective of this second RKI-SOEP (RKI-SOEP-2) study in November 2021-March 2022 was to estimate the prevalence of SARS-CoV-2-specific anti-spike and/or anti-nucleocapsid (anti-N) IgG antibodies (combined seroprevalence), past infection based on infection-induced seroprevalence (anti-N), and basic immunisation (at least two antigen contacts through vaccination or infection) in individuals aged ≥ 14 years. We also aimed to estimate under-reporting of infections.MethodsDried blood-spot specimens from a population-based sample embedded in a dynamic cohort, the Socio-Economic Panel (SOEP), were serologically analysed. Resulting serological data and self-reports via a questionnaire from the same individuals were used to estimate prevalences.ResultsCombined seroprevalence was 90.7% (95% CI: 89.7%-91.6%) without correction and 94.6% (95% CI: 93.6%-95.7%) with correction for sensitivity/specificity and antibody waning. While one in nine individuals had been infected (11.3%; 95% CI: 9.1%-13.5%), nine in 10 had a basic immunisation (90%; 95% CI: 88.9-90.9%), primarily due to vaccination. Population-weighted estimates differed by age, region, and socioeconomic deprivation. The under-reporting factor was estimated as 1.55 (95% CI: 1.3-1.8).ConclusionsWhen the SARS-CoV-2-Omicron wave was beginning, most people had been vaccinated, infected, or both. Large-scale vaccination, but not a high infection rate, was able to fill the immunity gap, especially in ≥ 65 year-olds who are known to be at higher risk of severe COVID-19. Our data point towards the need for targeted socioeconomically, demographically and regionally stratified mitigation strategies, including measures to enhance vaccine uptake.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Mercuri E, Schmid L, Poethko-Müller C, et al. Nationwide population-based infection- and vaccine-induced SARS-CoV-2 antibody seroprevalence in Germany in autumn/winter 2021/2022. Euro Surveill. 2025. PMID: 39790070. doi:10.2807/1560-7917.ES.2025.30.1.2400037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。